Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Gabapentin for the treatment of alcohol use disorder.

Mason BJ, Quello S, Shadan F.

Expert Opin Investig Drugs. 2018 Jan;27(1):113-124. doi: 10.1080/13543784.2018.1417383. Epub 2017 Dec 23. Review.

PMID:
29241365
2.

Emerging pharmacotherapies for alcohol use disorder.

Mason BJ.

Neuropharmacology. 2017 Aug 1;122:244-253. doi: 10.1016/j.neuropharm.2017.04.032. Epub 2017 Apr 25. Review.

3.

Existing and Future Drugs for the Treatment of the Dark Side of Addiction.

Koob GF, Mason BJ.

Annu Rev Pharmacol Toxicol. 2016;56:299-322. doi: 10.1146/annurev-pharmtox-010715-103143. Epub 2015 Oct 22. Review.

PMID:
26514207
4.

Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals.

Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ.

J Clin Invest. 2015 Aug 3;125(8):3193-7. doi: 10.1172/JCI79828. Epub 2015 Jun 29.

5.

Optical extinction efficiency measurements on fine and accumulation mode aerosol using single particle cavity ring-down spectroscopy.

Cotterell MI, Mason BJ, Preston TC, Orr-Ewing AJ, Reid JP.

Phys Chem Chem Phys. 2015 Jun 28;17(24):15843-56. doi: 10.1039/c5cp00252d. Epub 2015 May 28.

PMID:
26018300
6.

Direct measurements of the optical cross sections and refractive indices of individual volatile and hygroscopic aerosol particles.

Mason BJ, Cotterell MI, Preston TC, Orr-Ewing AJ, Reid JP.

J Phys Chem A. 2015 Jun 4;119(22):5701-13. doi: 10.1021/acs.jpca.5b00435. Epub 2015 May 22.

PMID:
25989469
7.

Thermoacoustic transduction in individual suspended carbon nanotubes.

Mason BJ, Chang SW, Chen J, Cronin SB, Bushmaker AW.

ACS Nano. 2015 May 26;9(5):5372-6. doi: 10.1021/acsnano.5b01119. Epub 2015 May 14.

PMID:
25961803
8.

Acamprosate, alcoholism, and abstinence.

Mason BJ.

J Clin Psychiatry. 2015 Feb;76(2):e224-5. doi: 10.4088/JCP.14com09632. No abstract available.

9.

Gabapentin treatment for alcohol dependence--reply.

Mason BJ, Goodell V, Shadan F.

JAMA Intern Med. 2014 Jul;174(7):1201-2. doi: 10.1001/jamainternmed.2014.1591. No abstract available.

PMID:
25003890
10.

Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity.

Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, García-Marchena N, Campos-Cloute R, Ruiz JJ, Romero P, Suárez J, Baixeras E, de la Torre R, Montesinos J, Guerri C, Rodríguez-Arias M, Miñarro J, Martínez-Riera R, Torrens M, Chowen JA, Argente J, Mason BJ, Pavón FJ, Rodríguez de Fonseca F.

Addict Biol. 2015 Jul;20(4):756-72. doi: 10.1111/adb.12156. Epub 2014 May 22.

PMID:
24854157
11.

Deviations from plane-wave Mie scattering and precise retrieval of refractive index for a single spherical particle in an optical cavity.

Mason BJ, Walker JS, Reid JP, Orr-Ewing AJ.

J Phys Chem A. 2014 Mar 20;118(11):2083-8. doi: 10.1021/jp5014863. Epub 2014 Mar 10.

PMID:
24580563
12.

Measurements of the evaporation and hygroscopic response of single fine-mode aerosol particles using a Bessel beam optical trap.

Cotterell MI, Mason BJ, Carruthers AE, Walker JS, Orr-Ewing AJ, Reid JP.

Phys Chem Chem Phys. 2014 Feb 7;16(5):2118-28. doi: 10.1039/c3cp54368d.

PMID:
24346588
13.

Gabapentin treatment for alcohol dependence: a randomized clinical trial.

Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A.

JAMA Intern Med. 2014 Jan;174(1):70-7. doi: 10.1001/jamainternmed.2013.11950.

14.

Comparison of the accuracy of aerosol refractive index measurements from single particle and ensemble techniques.

Mason BJ, King SJ, Miles RE, Manfred KM, Rickards AM, Kim J, Reid JP, Orr-Ewing AJ.

J Phys Chem A. 2012 Aug 23;116(33):8547-56. doi: 10.1021/jp3049668. Epub 2012 Aug 15.

PMID:
22856537
16.

A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S.

Neuropsychopharmacology. 2012 Jun;37(7):1689-98. doi: 10.1038/npp.2012.14. Epub 2012 Feb 29.

17.

A translational approach to novel medication development for protracted abstinence.

Mason BJ, Higley AE.

Curr Top Behav Neurosci. 2013;13:647-70. doi: 10.1007/7854_2012_201. Review.

PMID:
22351425
18.
19.

Treatment of alcohol dependence with drug antagonists of the stress response.

Higley AE, Koob GF, Mason BJ.

Alcohol Res. 2012;34(4):516-21.

20.

Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data.

Mason BJ, Lehert P.

Alcohol Clin Exp Res. 2012 Mar;36(3):497-508. doi: 10.1111/j.1530-0277.2011.01616.x. Epub 2011 Sep 6.

21.

Effects of chronic, heavy cannabis use on executive functions.

Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ.

J Addict Med. 2011 Mar;5(1):9-15. doi: 10.1097/ADM.0b013e31820cdd57.

22.

Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals.

Higley AE, Crane NA, Spadoni AD, Quello SB, Goodell V, Mason BJ.

Psychopharmacology (Berl). 2011 Nov;218(1):121-9. doi: 10.1007/s00213-011-2355-8. Epub 2011 May 24.

23.

An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions.

Crean RD, Crane NA, Mason BJ.

J Addict Med. 2011 Mar;5(1):1-8. doi: 10.1097/ADM.0b013e31820c23fa. Review.

24.

Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.

Mason BJ, Heyser CJ.

CNS Neurol Disord Drug Targets. 2010 Mar;9(1):23-32. Review.

25.

The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy.

Mason BJ, Lehert P.

Am J Addict. 2010 Mar-Apr;19(2):147-54. doi: 10.1111/j.1521-0391.2009.00013.x.

PMID:
20163387
26.

The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.

Mason BJ, Heyser CJ.

Expert Opin Drug Saf. 2010 Jan;9(1):177-88. doi: 10.1517/14740330903512943. Review.

PMID:
20021295
27.

Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets.

Mason BJ, Shaham Y, Weiss F, Le AD.

Alcohol. 2009 Nov;43(7):541-3. doi: 10.1016/j.alcohol.2009.09.024. No abstract available.

28.

Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy.

Mason BJ, Lehert P.

J Addict Med. 2009 Sep;3(3):164-71. doi: 10.1097/ADM.0b013e3181917d53.

PMID:
21769013
29.

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

Koob GF, Kenneth Lloyd G, Mason BJ.

Nat Rev Drug Discov. 2009 Jun;8(6):500-15. doi: 10.1038/nrd2828. Review.

30.

Telephone interventions for family caregivers of patients with dementia: what are best nursing practices?

Mason BJ, Harrison BE.

Holist Nurs Pract. 2008 Nov-Dec;22(6):348-54. doi: 10.1097/01.HNP.0000339346.26500.b9. Review.

PMID:
18981815
31.

Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.

Mason BJ, Light JM, Williams LD, Drobes DJ.

Addict Biol. 2009 Jan;14(1):73-83. doi: 10.1111/j.1369-1600.2008.00133.x. Epub 2008 Oct 9.

32.

Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics.

Mason BJ, Light JM, Escher T, Drobes DJ.

Psychopharmacology (Berl). 2008 Sep;200(1):141-50. doi: 10.1007/s00213-008-1192-x. Epub 2008 Jul 6.

33.
34.

Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.

Mason BJ, Crean R.

Expert Rev Neurother. 2007 Nov;7(11):1465-77. Review.

PMID:
17997696
35.

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group.

JAMA. 2006 May 3;295(17):2003-17.

PMID:
16670409
36.

Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.

Mason BJ, Goodman AM, Chabac S, Lehert P.

J Psychiatr Res. 2006 Aug;40(5):383-93. Epub 2006 Mar 20.

PMID:
16546214
37.

Understanding and treating alcohol dependence.

Johnson BA, Koob GF, Schuckit MA, Mason BJ, Ait-Daoud N.

Alcohol Clin Exp Res. 2006 Mar;30(3):567-84.

PMID:
16499499
38.

Sertraline treatment of co-occurring alcohol dependence and major depression.

Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M.

J Clin Psychopharmacol. 2006 Feb;26(1):13-20.

PMID:
16415699
39.

Rationale for combining acamprosate and naltrexone for treating alcohol dependence.

Mason BJ.

J Stud Alcohol Suppl. 2005 Jul;(15):148-56; discussion 140. Review.

PMID:
16223066
40.

How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE Study.

O'Malley SS, Martin DJ, Hosking JD, Mason BJ.

J Stud Alcohol Suppl. 2005 Jul;(15):66-71; discussion 65.

PMID:
16223058
41.

Acamprosate in the treatment of alcohol dependence.

Mason BJ.

Expert Opin Pharmacother. 2005 Oct;6(12):2103-15. Review.

PMID:
16197362
42.
43.

Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.

Mason BJ.

Eur Neuropsychopharmacol. 2003 Dec;13(6):469-75. Review.

PMID:
14636963
44.

Acamprosate.

Mason BJ.

Recent Dev Alcohol. 2003;16:203-15. Review. No abstract available.

PMID:
12638639
45.

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.

Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, Hunter JA, Boyeson MG.

Neuropsychopharmacology. 2002 Oct;27(4):596-606.

46.

Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry.

Xie S, Suckow RF, Mason BJ, Allen D, Cooper TB.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):143-9.

PMID:
12031840
47.

Potential neuroprotective effects of acamprosate.

Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR.

Alcohol Clin Exp Res. 2002 Apr;26(4):586-92.

PMID:
11981137
48.

Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.

Mason BJ.

J Clin Psychiatry. 2001;62 Suppl 20:42-8. Review.

49.

Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.

Boening JA, Lesch OM, Spanagel R, Wolffgramm J, Narita M, Sinclair D, Mason BJ, Wiesbeck GA.

Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):127S-131S. Review.

PMID:
11391061
50.

Natural control of Culex quinquefasciatus larvae in residential ditches by the copepod Macrocyclops albidus.

Marten GG, Nguyen M, Mason BJ, Ngo G.

J Vector Ecol. 2000 Jun;25(1):7-15.

PMID:
10925792

Supplemental Content

Loading ...
Support Center